Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease-related molecular biomarkers in the eye, announced today a Phase 2 grant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results